Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $97.23

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have received an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $100.31.

ITCI has been the subject of a number of research analyst reports. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC reiterated a “hold” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Michael Halstead sold 22,869 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ITCI. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the third quarter valued at $32,000. GAMMA Investing LLC increased its position in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in Intra-Cellular Therapies in the 3rd quarter valued at about $74,000. Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies in the third quarter valued at about $97,000. Finally, Quarry LP boosted its stake in Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 1,300 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Down 0.0 %

Shares of Intra-Cellular Therapies stock opened at $126.20 on Tuesday. The firm has a market cap of $13.38 billion, a PE ratio of -145.06 and a beta of 0.70. Intra-Cellular Therapies has a twelve month low of $62.78 and a twelve month high of $128.00. The business has a 50-day moving average price of $89.30 and a 200 day moving average price of $80.81.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. During the same quarter last year, the firm earned ($0.25) earnings per share. The firm’s quarterly revenue was up 39.0% compared to the same quarter last year. On average, sell-side analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.